Dr. Chemaly is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Box 402
Houston, TX 77030Phone+1 713-745-1116
Summary
- Roy Chemaly, MD, MPH, CMQ. Professor. Chief Infection Control Officer and Director of the Clinical Virology Research program. Dr. Chemaly’s interest include studies on the epidemiology, severity, prognosis, prevention and treatment of respiratory viral infections in immunocompromised cancer patients as well in the prevention of health care associated infections. Dr. Chemaly conducts clinical trials for the management and prevention of viral infections in cancer patients, Hematopoietic Cell Transplant (HCT) recipients, in particular, as well as on the composition of the upper respiratory tract microbiome as a risk factor for lower respiratory tract infections. He is also conducting clinical trials using CMV specific immuno-assays to predict CMV reactivation or progression. In addition, Dr. Chemaly and his lab team are conducting studies on whole genome sequencing for VRE, phages, and CMV to establish the transmission networks and the resistance and virulence genes associated with worse outcomes, respectively. His work in viral infections in HCT recipients has led to landmark publications in high impact journals like New England Journal of Medicine, Annals of Internal Medicine, Blood, and Clinical Infectious Diseases. He is the founder and past chair of the Transplant Infectious Diseases Special Interest Group of the American Society of Bone Marrow Transplantation and a member of the writing committee of the ASBMT guidelines for transplant infectious diseases, and the European Committee for Infections in Leukemia (ECIL 8). He is the co-chair of the Infection & Immune Reconstitution Working Committee of the ASTCT/CIBMTR, an executive member on the council for the International Immunocompromised Host Society (ICHS), and the scientific officer for the working group on respiratory viruses (ESGREV) of the European Society for Clinical Microbiology and Infectious Diseases (ESCMID). Funding sources: NCI/NIH, NIH subcontracts, Private industry, Institutional Awards.
Education & Training
- Cleveland Clinic FoundationFellowship, Infectious Disease, 1998 - 2001
- Zucker School of Medicine at Hofstra/Northwell at Staten Island University HospitalResidency, Internal Medicine, 1994 - 1998
- St Joseph's University Medical SchoolClass of 1992
Certifications & Licensure
- FL State Medical License 2021 - Present
- TX State Medical License 2002 - 2025
- NY State Medical License 1997 - 2003
- OH State Medical License 2000 - 2003
- American Board of Pathology Medical Microbiology
Awards, Honors, & Recognition
- Top Doctors:SE Texas Castle Connolly, 2013
Clinical Trials
- Intermittent Use of Aerosolized Ribavirin for Treatment of RSV Start of enrollment: 2003 Feb 01
- Cidofovir Instillation in Hematopoietic Stem Cell Transplant (HSCT) Recipients With Hemorrhagic Cystitis
- Respiratory Syncytial Virus - RSV Protocol Start of enrollment: 2011 Dec 28
- Join now to see all
Publications & Presentations
PubMed
- 2855 citationsGut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patientsVancheswaran Gopalakrishnan, Christine N. Spencer, Luigi Nezi, Alexandre Reuben, Miles C. Andrews
Science. 2018-01-05 - 89 citationsPosttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysisScott R. Goldsmith, Muhammad Bilal Abid, Jeffery J. Auletta, Asad Bashey, Amer Beitinjaneh
Blood. 2021-06-10 - 707 citationsLetermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell TransplantationFrancisco M. Marty, Per Ljungman, Roy F. Chemaly, Johan Maertens, Sanjeet Dadwal
The New England Journal of Medicine. 2017-12-06
Journal Articles
- The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant RecipientsRoy F Chemaly, Elizabeth Shpall, The Journal of Infectious Diseases
- Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplantation RecipientsSamuel L Aitken, Roy F Chemaly, Clinical Infectious Diseases
- Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical TrialsRoy F Chemaly, Kathleen M Mullane, Robin Avery, Raymund R Razonable, Clinical Infectious Diseases
- Join now to see all
Abstracts/Posters
- Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following AllotransplantationRoy Chemaly, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Freesia Study Design: JNJ-53718678 in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Upper Respiratory Tract61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- A Systematic and Critical Review of Bacteriophage Therapy Against Multi-Drug Resistant ESKAPE Organisms in HumansThe University of Texas, M. D. Anderson Cancer Center, Houston, Texas - 9/4/2012
Press Mentions
- 4 Questions About COVID-19 Vaccines and Bivalent Boosters, AnsweredSeptember 22nd, 2022
- COVID-19’s BA.4 and BA.5 Omicron Subvariants: 12 Questions, AnsweredJuly 14th, 2022
- Monkeypox 101: Insights for Cancer Patients and CaregiversJune 29th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: